The application of cardiac biomarkers along with the advances in imaging technology has helped minimizing need for invasive procedure.

New York, NY -- (SBWire) -- 04/24/2017 --Cardiovascular diseases is one of the leading cause of death accounting for one third of all deaths in developed countries. The increasing prevalence rate of cardiac biomarkers raises cost and medical burden on the society. The application of cardiac biomarkers along with the advances in imaging technology has helped minimizing need for invasive procedure. There are a variety of cardiac biomarkers to determine cardiac necrosis, cholesterol and lipoproteins level, thrombosis, cardiac necrosis and inflammation.

The cardiac biomarkers market is driven by the increasing number of products in pipeline, rise in the number of products approved, various funded projects and the company collaboration with clinical laboratories. EU-MASCARA (Markers for sub-clinical cardiovascular risk assessment), a project funded by the European Union has been able to apply new biomarkers which would be applied in novel biochip based assays for clinical use.

By detecting the early symptoms of cardiovascular diseases, the markers would help medical staff to assess patient's risk for developing the disease. Cardiovascular diseases being the number one cause of death worldwide, this particular effort could help cut healthcare costs and save lives.

Cardiac biomarkers are released in the blood during cardiac issues. These are detected in the blood through immunoassays which help to diagnose and treat the patient. Troponin I and T are the most common cardiac biomarkers used for detecting heart damage. But these biomarkers are less specific and may show elevated levels in other conditions. This has increased the number of research undertakings where researchers are trying to develop a potential biomarker. Some of the emerging cardiac biomarkers are hs-C-reactive protein (hs-CRP), B type natriuretic peptide (BNP), Myeloperoxidase (MPD) and Ischemic modified albumin (IMA).

In terms of geography, cardiac biomarkers market has been divided into five regions including North- America, Asia- Pacific, Middle-East & Africa, Latin America and Europe. The presence of major market players, technology advancements and research investments has made North America the dominating region for the cardiac biomarkers market. Moreover, there are many startups who are trying to enter the cardiac biomarkers market with new technologies and more sensitive tests. QLIDA Diagnostics a startup company is developing a mobile cardiac biomarker to detect heart attack or the likelihood of having one. Asia Pacific is expected to be the fastest growing region in the cardiac biomarkers market.

A Sample of this Report is Available Upon Request @http://www.persistencemarketresearch.com/samples/15223

Some of the cardiac biomarkers market participants are Critical Care Diagnostics Inc., Roche Diagnostics, Siemens Healthcare, Alere Inc., Abbott Laboratories, Bio-Rad Laboratories, Beckman Coulter, Becton, Dickinson and Company, Thermo Fisher Scientific, Randox laboratories, Critical Care Diagnostics Inc. and BioMerieux.

Critical Care Diagnostics Inc. received FDA approval for Presage ST2 Assay and is also working on an automated platform and point-of-care test. The lab test measures the level of ST2 protein in the bold and informs the physicians to assess the risk of heart failure. The product was launched with a view to reduce re-hospitalization by identifying high-risk of heart failure.

Request to View Tables of Content @http://www.persistencemarketresearch.com/toc/15223